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Abstract: A patient showing antibody-mediated rejection (AMR) with severe vasculitis, and 
massive proteinuria after kidney transplantation was treated with deoxyspergualine (DSG, 
Spanidin®, Nippon Kayaku). DSG showed marked efﬁ  cacy for this patient’s symptoms. We report 
on a patient for whom DSG was effective against AMR after renal transplantation.
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Introduction
Many aspects of the mechanisms of action of deoxyspergualine (DSG) remain unclear. 
Its remarkable efﬁ  cacy has occasionally been reported not only in the ﬁ  eld of trans-
plantation but also in that of collagen diseases. DSG is considered to be an effective 
treatment for the morbid condition in which an immune response apparently causes 
proteinuria.
Patient
The patient was a 47-year-old male ofﬁ  ce worker.
Past history
Emergency hemodialysis as a result of pulmonary edema was initiated in 2001 to treat 
renal disease of unknown origin. The patient had not been followed up by physicians, 
although proteinuria was diagnosed 10 years previously. He was maintained on hemo-
dialysis. There were no noteworthy complications other than hypertension.
Clinical course (Figure 1)
The patient underwent kidney transplantation overseas on August 2003. His progress 
was checked in an outpatient ward in our department, starting in September 2003. 
The post-transplant immunosuppressive induction regimen consisted of cyclosporine 
(CsA), mycophenolate mofetil (MMF), and methylprednisolone (MP). Proteinuria 
was recognized as 500–800 mg total urine protein in a 24-hour collection one month 
after the transplant. Although a serum creatinine level (sCr) of 1.1 mg/dL indicated a 
favorable function of the transplanted kidney, 6 months postoperatively on February 
2004, the urinary protein level tended to increase gradually, eventually reaching at least 
3 g/day on April 2004. Steroid pulse therapy (500 mg × 2) was administered during 
this period, and at the same time CsA was temporarily changed to tacrolimus (FK506). Therapeutics and Clinical Risk Management 2008:4(3) 642
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However, because the patient had severe neurological 
symptoms, FK506 was discontinued and CsA was restarted. 
From this time onward, sCr levels also rose gradually. Since 
sCr level increased from 1.2 mg/dL to 1.6 mg/dL on April 
2004, the transplanted kidney was biopsied after the patient 
was hospitalized on May 2004. The biopsy revealed anti-
body-mediated rejection and severe vasculitis (Figure 2), 
and DSG was administered at a dose of 5 mg/kg for 5 days 
on June 2004. Thereafter, his condition was again checked 
in an outpatient ward. Because proteinuria increased with 
elevation of sCr from 1.4 mg/dL to 1.7 mg/dL, despite a 
transient improvement, DSG was again administered at 
a dose of 5 mg/kg for 5 days on October 2004. After the 
second dose of DSG, a dramatic improvement in protein-
uria was recognized, and urinary protein ﬁ  nally decreased 
to zero. On April 2005, renal biopsy was repeated. There 
was no evidence of a rejection and the vasculitis had 
improved markedly with disappearance of C4d deposition. 
We switched CsA to FK506 on April 2005 again; however, 
the patient had no complaints such as neuralgia similar to the 
ﬁ  rst switch. No antihypertensive drugs, such as angiotensin 
receptor blockers (ARB), were used during our patient’s 
clinical course.
Immunological examination
Cross-matching test results before transplantation were all 
negative. With regard to post-transplant antibodies, Luminex 
(One Lamda, CA, USA) tests revealed the presence of mas-
sive amounts of A11, B41, and CREG was 1C1, but no 
changes in the types of antibodies before, compared with 
after, administration of DSG. We guess that 1C1 CREG are 
main donor-speciﬁ  c antibodies (DSA).
Discussion
Many aspects of the mechanisms of action of DSG remain 
unclear. However, its remarkable efﬁ  cacy has occasionally 
Figure 1 Clinical course. After the 2nd dose of DSG treatment, a dramatic improvement in proteinuria was recognized, and urinary protein ﬁ  nally decreased to zero. On this 
occasion, renal biopsy was repeated. There was no evidence of a rejection and the vasculitis had improved markedly without C4d staining.
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been reported not only in the ﬁ  eld of transplantation but 
also in that of collagen diseases. It seems that DSG exerts 
immunosuppressive effects that differ distinctly from those 
of CsA and FK506, which are calcineurin inhibitors (CNI), 
and from those of MMF, which are metabolic antagonists. 
Suppression of intracellular NF-κB has been described as 
being representative of the mechanisms of DSG. In recent 
years, binding of DSG to an Hsp family (HSP 70, 90) 
molecule, a heat shock protein, was reported to suppress 
the antigen-presenting capacity of dendritic cells and the 
expressions of immunoglobulins on these cells (Nadler 
et al 1992, 1995).
There have been many reports on DSG-related improve-
ments in clinical cases with severe vasculitis, which include 
Wegener granulomatosis and crescentic glomerulonephritis 
(Birck et al 2003; Shimitt et al 2005; Imai et al 2006). 
Researchers have also reported that all such patients 
showed severe vasculitis and cellular inﬁ  ltration on biopsy, 
and remarkable improvements in these conditions after 
treatment with DSG. We consider that suppression of 
antibody-producing cells directly suppressed inﬁ  ltrating 
cells in the kidney and also indirectly suppressed antibody 
production, both of which cause these conditions, thereby 
markedly improving the pathologic condition.
The advent of various immunosuppressive agents and 
the development of immunological monitoring have mark-
edly improved outcomes of renal transplantation and have 
decreased post-transplant rejection, but we still encounter 
unexpected rejections. In particular, the rejection recog-
nized in the present patient, ie, steroid-resistant severe 
antibody-mediated and vascular rejections, produced severe 
clinical symptoms, so that ﬁ  nding appropriate treatment was 
extremely challenging. Suppressing an immunologically 
activated condition, in which aggressive pathways involv-
ing interaction of T and B cells has already been triggered, 
leading to continuous production of anti-HLA antibodies, 
is very difﬁ  cult. The usefulness of massive administration 
of γ-globulin and of conventional plasma exchange has also 
been more widely recognized, as has the efﬁ  cacy of ritux-
imab (anti-CD20 antibody). Saving the transplanted kidney 
Figure 2 Pathological ﬁ  ndings. Before DSG treatment: Specimen revealed aggressive cellular inﬁ  ltration (black arrows) of arterial vessel wall and severe capillaritis and tubulitis, 
that suggests antibody mediated rejection with vasculitis. C4d deposition was also diffusely immunostained in peritubular capillaries. After DSG treatment: No rejection was 
shown in the specimen after DSG treatment. C4d deposition also disappeared after treatment.
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by combining these methods has become more feasible. On 
the basis of our experience with the patient described herein, 
we consider that DSG should be considered as one of the 
treatment alternatives for such severe rejection reactions. The 
morbid condition, in which allogenic anti-HLA antibodies 
produced after transplantation directly attack the intravas-
cular wall of the transplanted kidney, resembles the morbid 
condition of vasculitis in collagen diseases like Wegener’s 
granulomatosis. DSG is also expected to be efﬁ  cacious for 
such conditions.
Conclusions
We reported on a patient in whom DSG was effective against 
AMR after renal transplantation.
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